Bivalirudin
Active ingredient: Bivalirudin
In short: Bivalirudin Injection is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
What is Bivalirudin used for?
Bivalirudin Injection is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
Bivalirudin dosage
The recommended dose of Bivalirudin Injection is an intravenous bolus dose of 0.75 mg/kg, followed immediately by a maintenance infusion of 1.75 mg/kg/h for the duration of the procedure. Five minutes after the bolus dose has been administered, assess activated clotting time (ACT) to determine if an additional bolus of 0.3 mg/kg is needed.
Consider extending duration of infusion following PCI at 1.75 mg/kg/h for up to 4 hours post- procedure in patients with ST segment elevation MI (STEMI).
Bolus Dose:
No reduction in the bolus dose is needed for any degree of renal impairment.
Maintenance Infusion:
In patients with creatinine clearance less than 30 mL/min (by Cockcroft Gault equation), reduce the infusion rate to 1 mg/kg/h.
In patients on hemodialysis, reduce the infusion rate to 0.25 mg/kg/h .
Bivalirudin Injection is a ready-to-use sterile solution for intravenous use only.
Inspection of Container
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Once removed from the refrigerator, Bivalirudin Injection may be stored at room temperature 20º to 25°C (68º to 77°F) for up to 72 hours . Discard any unused portion.
Drug Compatibilities
No incompatibilities have been observed with administration sets.
Do not administer the drugs listed in Table 1 in the same intravenous line with Bivalirudin Injection.
Table 1. Drugs Not for Administration in the Same Intravenous Line with Bivalirudin Injection
Alteplase
Amiodarone HCl
Amphotericin B
Chlorpromazine HCl
Diazepam
Dobutamine
Prochlorperazine Edisylate
Reteplase
Streptokinase
Vancomycin HCl
How to take Bivalirudin — instructions & advice from the label
Advise patients to watch carefully for any signs of bleeding or bruising and to report these to their healthcare provider when they occur.
Manufactured for:
Par Health USA
Rochester, MI 48307
Product of India
R12/2025
Warnings & precautions
Do not take this medicine if: Bivalirudin Injection is contraindicated in patients with:
Significant active bleeding;
Hypersensitivity to Bivalirudin Injection or its components .
Bivalirudin increases the risk of bleeding . Bivalirudin’s anticoagulant effect subsides approximately one hour after discontinuation .
An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of bivalirudin in gamma brachytherapy .
Bivalirudin side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In the BAT trials, 79 of the 2161 (3.7%) of subjects undergoing PCI for treatment of unstable angina and randomized to bivalirudin experienced intracranial bleeding, retroperitoneal bleeding, clinically overt bleeding with a decrease in hemoglobin greater than 3 g/dL or leading to a transfusion of greater than 2 units of blood.
Immunogenicity/Re-Exposure
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to bivalirudin in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
In in vitro studies, bivalirudin exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS. …
Drug interactions
In clinical trials in patients undergoing PCI, co-administration of bivalirudin with heparin, warfarin, thrombolytics, or GPIs was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
About this medicine
Bivalirudin Injection contains bivalirudin trifluoroacetate, which is a specific and reversible direct thrombin inhibitor. Bivalirudin trifluoroacetate is a synthetic, 20 amino acid peptide salt, with the chemical name of D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparagylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine trifluoroacetate. Each molecule of bivalirudin trifluoroacetate contains 1.7 to 2.6 equivalents of trifluoroacetic acid. The molecular formula of bivalirudin free base is C98H138N24O33 and its molecular weight is 2180.32 Daltons (anhydrous free base peptide). The structural formula of bivalirudin free base is
Figure 1: Structural Formula of Bivalirudin
Bivalirudin Injection is supplied as a refrigerated, ready-to-use, sterile solution packaged in a 50 mL single-dose vial. Each milliliter of Bivalirudin Injection contains 5 mg bivalirudin (as trifluoroacetate salt)*, 0.8 mg sodium acetate trihydrate, 100 mg polyethylene glycol 400, and Water for Injection. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 91cf9d00-29e0-4357-a184-f70026c47edb. Read the full official label on DailyMed.
Related medicines
Apixaban Warfarin Fondaparinux Dabigatran Dalteparin Edoxaban Enoxaparin Heparin